Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial

Ähnliche Einträge

• Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma
  von: Takahiro Kinami, et al.
  Veröffentlicht: (2024)
• Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants
  von: Tasuku Nakabori, et al.
  Veröffentlicht: (2024)
• A case of biopsy‐proven acute interstitial nephritis following atezolizumab‐bevacizumab treatment of advanced unresectable hepatocellular carcinoma
  von: Reema Patel, et al.
  Veröffentlicht: (2024)
• Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial
  von: Toshifumi Tada, et al.
  Veröffentlicht: (2024)
• Patient‐reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials
  von: Bradley D. Menz, et al.
  Veröffentlicht: (2025)